AudioScholar Dermatology Weekly

AudioScholar
  • 0.0 (0)
  • Medicine
  • Weekly

Dermatology — a weekly podcast briefing of the most significant peer-reviewed dermatology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

  1. 2d ago

    This Week in Dermatology — Oct 30, 2026

    Editor's Pick: 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study (Journal of the American Academy of Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cutaneous oncology and immunotherapy, long-term management of inflammatory skin disease, and the harder edges of blistering, metabolic and genetic skin condition… This week's papers: 1. Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial. — Nature Medicine 2026 2. Intralesional cemiplimab for patients with early-stage cutaneous squamous cell carcinoma: Results from a dose-escalation study with expansion cohorts. — Journal of the American Academy of Dermatology 2026 3. Targeted and Immune-Based Therapies in Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis. — JAMA Dermatology 2026 4. A randomised double-blind placebo-controlled trial of topical menthol for pain relief during photodynamic therapy. — Clinical and Experimental Dermatology 2026 5. 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study. — Journal of the American Academy of Dermatology 2026 6. Phenome-wide Longitudinal Association Study of Hospital-recorded Comorbidity in Psoriasis. — British Journal of Dermatology 2026 7. Vitamin D status and systemic inflammatory burden as a predictor of biologic treatment response in psoriasis -A pilot study in Northern Ireland. — Clinical and Experimental Dermatology 2026 8. Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid. — JAMA Dermatology 2026 9. Estrogen Use and Porphyria Cutanea Tarda. — JAMA Dermatology 2026 10. Understanding the Experiences and Needs of Parents With Children With Epidermolysis Bullosa. A Qualitative Study to Inform the Development of a Self-help Toolk… — British Journal of Dermatology 2026 Listen at https://audioscholar.cc/episode/k7q4tr8fad

  2. Oct 24

    This Week in Dermatology — Oct 23, 2026

    Editor's Pick: Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa (Journal of the American Academy of Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning a major push in hidradenitis suppurativa, new targeted therapies and treatment selection in inflammatory skin disease, and risk stratification and staging in ski… This week's papers: 1. Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa. — Journal of the American Academy of Dermatology 2026 2. HiSQOL-mini: Development and Validation of a Shortened Version of the Hidradenitis Suppurativa Quality of Life (HiSQOL) Instrument. — British Journal of Dermatology 2026 3. Optimizing surgery in hidradenitis suppurativa. — Journal of the European Academy of Dermatology and Venereology 2026 4. Hidradenitis suppurativa skin microbiome: In-depth analysis and modulation by systemic therapies. — Journal of the European Academy of Dermatology and Venereology 2026 5. Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST. — Journal of the American Academy of Dermatology 2026 6. Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, rand… — Journal of the American Academy of Dermatology 2026 7. Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents. — Journal of the American Academy of Dermatology 2026 8. Psoriasis: Which therapy for which patient, updated, part II. Focus on special populations and chronic infections. — Journal of the American Academy of Dermatology 2026 9. Evaluating the Performance of Melanoma Risk Prediction Models. — JAMA Dermatology 2026 10. Extramammary Paget's Disease With Bilateral Sentinel Lymph Node Biopsy: a Multicenter Study of Lymphatic Patterns and Outcomes. — Clinical and Experimental Dermatology 2026 Listen at https://audioscholar.cc/episode/n9uy8g4nbs

  3. Oct 17

    This Week in Dermatology — Oct 16, 2026

    Editor's Pick: Cancer Risk in Patients With Overall and Site-Specific Lichen Planus (JAMA Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cancer risk in chronic inflammatory dermatoses and melanoma diagnostics, the expanding role of JAK inhibition and phototherapy in pigmentary and sclerosing disea… This week's papers: 1. Cancer Risk in Patients With Overall and Site-Specific Lichen Planus. — JAMA Dermatology 2026 2. Female genital lichen sclerosus. — Journal of the European Academy of Dermatology and Venereology 2026 3. Experience-based recommendations for the diagnosis and management of early-stage nail unit melanoma. — Journal of the European Academy of Dermatology and Venereology 2026 4. Real-time assessment of mitotic rate in malignant melanoma by ex vivo confocal microscopy. — Clinical and Experimental Dermatology 2026 5. Upadacitinib Combined with NB-UVB for Non-Segmental Vitiligo: A Single-Center Prospective Study. — Clinical and Experimental Dermatology 2026 6. Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study. — Journal of Investigative Dermatology 2026 7. UVA1 Phototherapy in a national reference center:A 10-year systematical analysis. — Dermatology 2026 8. LABD97 IgG ELISA increases sensitivity of ELISA serologic testing for the diagnosis of bullous pemphigoid. — Journal of the American Academy of Dermatology 2026 9. Device-Free Auricular Acupressure for Rosacea: A Randomized Clinical Trial. — JAMA Dermatology 2026 10. Optimizing therapy in hidradenitis suppurativa: Combination, sequencing and treat-to-target. — Journal of the European Academy of Dermatology and Venereology 2026 Listen at https://audioscholar.cc/episode/44qect7b45

  4. Oct 10

    This Week in Dermatology — Oct 9, 2026

    Editor's Pick: Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome (JAMA Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cutaneous oncology and prevention, autoimmune blistering disease, and the expanding therapeutic toolkit for chronic inflammatory skin disease. Let's dive in. This week's papers: 1. Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome. — JAMA Dermatology 2026 2. Comparison of efficacy and tolerability of hedgehog pathway inhibitors for locally advanced basal cell carcinoma: An expert opinion in the new age of immunothe… — Journal of the American Academy of Dermatology 2026 3. Melanoma Prevention Among Children of Melanoma Survivors: A Randomized Clinical Trial. — JAMA Dermatology 2026 4. Pemphigoid After Immune Checkpoint Inhibitors and Other Anti-Neoplastic Medications: A Danish Nationwide Case-Control Study. — Clinical and Experimental Dermatology 2026 5. Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab. — Journal of the European Academy of Dermatology and Venereology 2026 6. Assessment of the Sustained Response to Systemic Treatment for Atopic Dermatitis in Patients Who Achieved Disease Remission: A Systematic Review and Network Me… — British Journal of Dermatology 2026 7. Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospect… — Acta Dermato-Venereologica 2026 8. Effect of Biologic Therapy on Depression and Anxiety Symptoms in Patients With Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analys… — British Journal of Dermatology 2026 9. Upcoming novel treatments for hidradenitis suppurativa: An overview of the pipeline. — Journal of the European Academy of Dermatology and Venereology 2026 10. Dupilumab as Add-On Therapy for JAK Inhibitor-Relapsed Pediatric Alopecia Areata: A Case Series. — Pediatric Dermatology 2026 Listen at https://audioscholar.cc/episode/pqm6jewv45

  5. Oct 3

    This Week in Dermatology — Oct 2, 2026

    Editor's Pick: Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA) (Journal of the American Academy of Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning skin cancer and immunotherapy, immune-related toxicities, and practical consensus guidance for infections, inflammatory disease and hair loss. Let's dive in. This week's papers: 1. Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). — Nature Medicine 2026 2. Collaborative Multicenter Prognostication and Staging System for Cutaneous Squamous Cell Carcinoma (COMPASS-SCC). — Journal of the American Academy of Dermatology 2026 3. Autoimmune Bullous Disorders Associated With Immune Checkpoint Inhibitors: A Retrospective Review of a Single Center Cohort Over the Past Decade. — Clinical and Experimental Dermatology 2026 4. Immune-related adverse events with mogamulizumab in cutaneous T-cell lymphoma: A multicentre study. — Journal of the European Academy of Dermatology and Venereology 2026 5. Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blin… — Journal of the American Academy of Dermatology 2026 6. IADVL consensus recommendations on Trichophyton indotineae infections: Using modified Delphi method. — Journal of the European Academy of Dermatology and Venereology 2026 7. A single-dose topical therapy cures scabies in a human-relevant porcine model. — Science Translational Medicine 2026 8. Summary of Best Evidence for Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. — Acta Dermato-Venereologica 2026 9. Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement. — JAMA Dermatology 2026 10. A Clinical Approach to Psychodermatologic Conditions: From Recognition to Treatment. — Journal of the American Academy of Dermatology 2026 Listen at https://audioscholar.cc/episode/avb22n28a4

  6. Sep 26

    This Week in Dermatology — Sep 25, 2026

    Editor's Pick: Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial (JAMA Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning psoriasis across the lifespan, targeted small molecules moving into orphan inflammatory dermatoses, and the less glamorous but equally consequential business of… This week's papers: 1. Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study. — British Journal of Dermatology 2026 2. Clinical characteristics and risk factors for a distinct pustular psoriasis flare after withdrawal of biologics in plaque psoriasis. — Journal of the American Academy of Dermatology 2026 3. Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial. — JAMA Dermatology 2026 4. Upadacitinib for Palmoplantar Pustulosis: An Open-label, Assessor-blinded Feasibility Study Using Historic Control Data (JAKPPPOT). — British Journal of Dermatology 2026 5. Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis. — Journal of the American Academy of Dermatology 2026 6. Early systemic intervention for vitiligo: A prospective bicentric interventional study. — Journal of the European Academy of Dermatology and Venereology 2026 7. Chronic Spontaneous Urticaria in Finland - A Nationwide Registry Study on Epidemiology and Treatment Patterns in Secondary Care. — Acta Dermato-Venereologica 2026 8. Consensus recommendations for Trichophyton indotineae: A modified Delphi study. — Journal of the European Academy of Dermatology and Venereology 2026 9. Best Practices for Managing Pseudofolliculitis Barbae: An Expert Consensus Delphi Study. — JAMA Dermatology 2026 10. Skin Cancer Risk Stratification and Outcomes in Swedish Solid Organ Transplant Recipients. — Journal of Investigative Dermatology 2026 Listen at https://audioscholar.cc/episode/q2vwq6q8yd

  7. Sep 19

    This Week in Dermatology — Sep 18, 2026

    Editor's Pick: Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data (British Journal of Dermatology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the comparative safety and durability of biologics in inflammatory skin disease, the real-world performance of our immunomodulatory workhorses in severe and rare… This week's papers: 1. Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study fro… — British Journal of Dermatology 2026 2. Real-World Treatment Response to Adalimumab and Secukinumab in Chinese Adults with Hidradenitis Suppurativa: A Retrospective Cohort Study. — Dermatology 2026 3. Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis. — JAMA Dermatology 2026 4. Short-term prognostic factors of rituximab combined with glucocorticoids in the treatment of pemphigus: A multicenter retrospective study. — Journal of the American Academy of Dermatology 2026 5. Adverse Events and Real-World Outcomes of Intravenous Immunoglobulin in Dermatologic Diseases: A 20-Year Cohort Study. — Clinical and Experimental Dermatology 2026 6. Updosed Omalizumab in Chronic Spontaneous Urticaria With or Without Symptomatic Dermographism. — Clinical and Experimental Dermatology 2026 7. Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion. — Journal of the European Academy of Dermatology and Venereology 2026 8. Adverse pregnancy outcomes in women with atopic dermatitis: A systematic review and meta-analysis. — Journal of the European Academy of Dermatology and Venereology 2026 9. Systematic Review and Meta-Analysis of Thyroid Disease in Children With Vitiligo. — Pediatric Dermatology 2026 10. Precision Medicine for Somatic Mutation-Driven Vascular Anomalies. — British Journal of Dermatology 2026 Listen at https://audioscholar.cc/episode/qnv6j3y7md

  8. Sep 12

    This Week in Dermatology — Sep 11, 2026

    Editor's Pick: Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study (British Journal of Dermatology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning immune-targeted therapy — where one major trial failed and several others refine how we use the drugs we already have — plus skin cancer surgery and systemic com… This week's papers: 1. Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-… — British Journal of Dermatology 2026 2. Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial. — Journal of the American Academy of Dermatology 2026 3. Pediatric Alopecia Areata and JAK Inhibitors: Bridging the Gap Between Evidence and Practice. — Journal of the American Academy of Dermatology 2026 4. Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis. — JAMA Dermatology 2026 5. Inflammatory Bowel Disease and Interleukin-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. — JAMA Dermatology 2026 6. Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study. — British Journal of Dermatology 2026 7. Blood proteomics links systemic inflammation with early atherosclerosis in moderate-to-severe atopic dermatitis. — Journal of Investigative Dermatology 2026 8. Advances in the diagnosis and management of skin and soft tissue infections. — BMJ 2026 9. Comparison of sunscreen products for babies and children with those for adults. — Dermatology 2026 10. Veterans' Willingness to Use Home-based Telehealth and AI for Dermatology. — Journal of Investigative Dermatology 2026 Listen at https://audioscholar.cc/episode/srvpdgsayz

See All (25)

About

Dermatology — a weekly podcast briefing of the most significant peer-reviewed dermatology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Information